Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity

Cancer Gene Therapy

Volumn 13, Issue 2, 2006, Pages 203-214

  Kaliberov, S A ^a   Chiz, S ^a   Kaliberova, L N ^a   Krendelchtchikova, V ^a   Della Manna, D ^a   Zhou, T ^b   Buchsbaum, D J ^a  

^a The University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Adenoviral directed enzyme prodrug therapy; Cytosine deaminase; Tumor necrosis factor related apoptosis inducing ligand; Uracil phosphoribosyltransferase

Indexed keywords

ADENOVIRUS VECTOR; CYTOSINE DEAMINASE; FLUOROURACIL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TRA 8; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; EVALUATION; GENE EXPRESSION; GENE FUSION; GLIOMA; HUMAN; LIGAND BINDING; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; XENOGRAFT;

ADENOVIRIDAE; ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; CELL LINE, TUMOR; CYTOSINE DEAMINASE; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GLIOMA; HUMANS; IMMUNOTHERAPY; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; PANCREATIC NEOPLASMS; PENTOSYLTRANSFERASES; PRODRUGS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR;

ADENOVIRIDAE; AGOUTI PACA; ANIMALIA;

EID: 30944438876     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700874     Document Type: Article

References (39)

1. Shirakawa T, Gardner TA, Ko SC, Bander N, Woo S, Gotoh A et al. Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model. J Urol 1999; 162: 949-954.
2. Lawrence TS, Rehemtulla A, Ng EY, Wilson M, Trosko JE, Stetson PL. Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-fluorocytosine. Cancer Res 1998; 58: 2588-2593.
3. Koyama F, Sawada H, Fuji H, Hamada H, Hirao T, Ueno M et al. Adenoviral transfer of Escherichia coli uracil phosphoribosyltransferase (UPRT) gene to modulate the sensitivity of the human colon cancer cells to 5-fluorouracil. Eur J Cancer 2000; 36: 2403-2410.
4. Kawamura K, Tasaki K, Hamada H, Takenaga K, Sakiyama S, Tagawa M. Expression of Escherichia coli uracil phosphoribosyltransferase gene in murine colon carcinoma cells augments the antitumoral effect of 5-fluorouracil and induces protective immunity. Cancer Gene Ther 2000; 7: 637-643.
5. Tiraby M, Cazaux C, Baron M, Drocourt D, Reynes JP, Tiraby G. Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine. FEMS Microbiol Lett 1998; 167: 41-49.
6. Adachi Y, Tamiya T, Ichikawa T, Terada K, Ono Y, Matsumoto K et al. Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine. Hum Gene Ther 2000; 11: 77-89.
7. Chung-Faye GA, Chen MJ, Green NK, Burton A, Anderson D, Mautner V et al. In vivo gene therapy for colon cancer using adenovirus-mediated transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Therapy 2001; 8: 1547-1554.
8. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7: 954-960.
9. Buchsbaum DJ, Zhou T, Grizzle WE, Oliver PG, Hammond CJ, Zhang S et al. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 2003; 9: 3731-3741.
10. Kaliberov S, Stackhouse MA, Kaliberova L, Zhou T, Buchsbaum DJ. Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells. Gene Therapy 2004; 11: 658-667.
11. Pederson LC, Buchsbaum DJ, Vickers SM, Kancharla SR, Mayo MS, Curiel DT et al. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. Cancer Res 1997; 57: 4325-4332.
12. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enz Regul 1984; 22: 27-55.
13. Dressler V, Muller G, Suhnel J. CombiTool - a new computer program for analyzing combination experiments with biologically active agents. Comput Biomed Res 1999; 32: 145-160.
14. Brandes AA. State-of-the-art treatment of high-grade brain tumors. Semin Oncol 2003; 6: 4-9.
15. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004; 363: 1049-1057.
16. Hawkins CJ. TRAIL and malignant glioma. Vitam Horm 2004; 67: 427-542.
17. Stackhouse MA, Pederson LC, Grizzle WE, Curiel DT, Gebert J, Haack K et al. Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models. Gene Therapy 2000; 7: 1019-1026.
18. Yazawa K, Fisher WE, Brunicardi FC. Current progress in suicide gene therapy for cancer. World J Surg 2002; 26: 783-789.
19. Kambara H, Tamiya T, Ono Y, Ohtsuka S, Terada K, Adachi Y et al. Combined radiation and gene therapy for brain tumors with adenovirus-mediated transfer of cytosine deaminase and uracil phosphoribosyltransferase genes. Cancer Gene Ther 2002; 9: 840-845.
20. Patterson AV, Saunders MP, Greco O. Prodrugs in genetic chemoradiotherapy. Curr Pharm Des 2003; 9: 2131-2154.
21. Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renee N et al. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995; 13: 1663-1670.
22. Harris BE, Song R, Soong SJ, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50: 197-201.
23. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6: 1322-1327.
24. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H et al. Thymidylate synthetase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1996; 14: 176-182.
25. Inaba M, Naoe Y, Mitsuhashi J. Mechanisms for 5-fluorouracil resistance in human colon cancer DLD-1 cells. Biol Pharm Bull 1998; 21: 569-573.
26. Wang FS, Aschele C, Sobrero A, Chang YM, Bertino JR. Decreased folylpolyglutamate synthetase expression: a novel mechanism of fluorouracil resistance. Cancer Res 1993; 53: 3677-3680.
27. Koyama F, Sawada H, Hirao T, Fujii H, Hamada H, Nakano H. Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of Escherichia coli cytosine deaminase gene and Escherichia coli uracil phosphoribosyltransferase gene with 5-fluorocytosine. Cancer Gene Ther 2000; 7: 1015-1022.
28. Kanai F, Kawakami T, Hamada H, Sadata A, Yoshida Y, Tanaka T et al. Adenovirus mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res 1998; 58: 1946-1951.
29. Miyagi T, Koshida K, Hori O, Konaka H, Katoh H, Kitagawa Y et al. Gene therapy for prostate cancer using the cytosine deaminase/uracil phosphoribosyltransferase suicide system. J Gene Med 2003; 5: 30-37.
30. Kurozumi K, Tamiya T, Ono Y, Otsuka S, Kambara H, Adachi Y et al. Apoptosis induction with 5-fluorocytosine/cytosine deaminase gene therapy for human malignant glioma cells mediated by adenovirus. J Neurooncol 2004; 66: 117-127.
31. Zhang SN, Yuan SZ, Zhu ZH, Wen ZF, Huang ZQ, Zeng ZY. Apoptosis induced by 5-flucytosine in human pancreatic cancer cells genetically modified to express cytosine deaminase. Acta Pharmacol Sin 2000; 21: 655-659.
32. Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R, Zhou T. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 2003; 22: 2034-2044.
33. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999; 59: 734-741.
34. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162.
35. Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 2002; 62: 5800-5806.
36. von Haefen C, Gillissen B, Hemmati PG, Wendt J, Guner D, Mrozek A et al. Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway. Oncogene 2004; 23: 8320-8332.
37. Bonavida B, Ng CP, Jazirehi A, Schiller G, Mizutani Y. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics. Int J Oncol 1999; 15: 793-802.
38. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang H-JS. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 2000; 60: 847-853.
39. Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E, Bhalla K. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood 2000; 96: 3900-3906.